Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Naltrexone versus buprenorphine for opioid use disorder

Date Released: 3月 21 2018

This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts.

Dr. SaxonDr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association’s Council on Addiction Psychiatry.

Segment on naltrexone versus buprenorphine for opioid use disorder (Dr. Saxon):

  1. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309.
  2. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197.

Andrew Saxon, MD Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].

Monoclonal antibodies to prevent migraine; Oral fecal microbiota transplant for C. diff infection

Date Released: 3月 7 2018

Today’s episode of UpToDate Talk features Dr. Jerry Swanson discussing novel monoclonal antibody therapies to prevent migraines, and Dr. Ciarán Kelly discussing oral fecal microbiota transplantation for the treatment of C. difficile infection. The second segment begins at 14:58. Dr. Nancy Sokol hosts.

Dr. SwansonDr. Jerry Swanson is Professor of Neurology at the Mayo Clinic College of Medicine, where he's a consultant neurologist with a special interest in patients with headaches, including migraine. He is an UpToDate section editor in the neurology specialty.
Dr. KellyDr. Ciarán Kelly is Professor of Medicine at Harvard Medical School and Director of Gastroenterology Fellowship Training at Beth Israel Deaconess Medical Center in Boston. His clinical and research interests are in intestinal infection and inflammation. He is an UpToDate author of several topics covering C. difficile infection and celiac disease.

Segment on monoclonal antibodies to prevent migraine (Dr. Swanson):

  1. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017; 377:2113.
  2. Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377:2123.

Segment on oral fecal microbiota transplant for C. diff infection (Dr. Kelly):

  1. Kao D, Roach B, Silva M, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA 2017; 318:1985.

Jerry Swanson, MD, MHPE Nothing to disclose

Ciarán Kelly, MD Consultant/Advisory Boards: Cellimmune [Celiac disease (Immune therapy in development)]; Cour Pharmaceuticals [Celiac disease (Immune therapy in development)]; Glutenostics [Celiac disease diagnostic]; Immunogenx [Celiac disease (Glutenase therapy in development)]; Innovate [Celiac disease (Larazotide acetate therapy in development)]; Merck [C difficile infection (Fidaxomicin, Bezlotoxumab)]; Seres Therapeutics [C difficile infection (prophylactic agent in development)]; Summit [C difficile infection (Ridinilazole in development)]; Synthetic Biologies [C difficile infection (Beta lactamase inhibitor in development)]; Takeda [Celiac disease (Therapies in development)]. Grant/Research/Clinical Trial Support: Aptalis [Celiac disease (Viokase pancrelipase)]; Institut Merieux [C difficile infection (ultrasensitive toxin assays); Merck [C difficile infection (Fidaxomicin, Bezlotoxumab); National Institutes of Health [C difficile (vaccine development, ultrasensitive toxin assays)]. Equity Ownership/Stock Options: Cour Pharmaceuticals [Celiac disease (Immune therapy in development)]; Glutenostics [Celiac disease diagnostic].

Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

Date Released: 2月 21 2018

Today’s UpToDate Talk episode features discussions related to three papers published in the New England Journal of Medicine. Dr. Jess Mandel discusses anticoagulation options for cancer-associated venous thromboembolism, and Dr. George Mallory discusses two studies of tezacaftor-ivacaftor in patients with cystic fibrosis. Segment two begins at 11:32. Dr. Helen Hollingsworth hosts.

Dr. MandelDr. Jess Mandel is Professor of Medicine and Vice Chair of the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of California San Diego. He is Section Editor for UpToDate topics on pulmonary vascular disease.
Dr. MalloryDr. George Mallory is Professor of Pediatrics at Baylor College of Medicine, and Section Editor for UpToDate topics on pediatric pulmonology.

Segment on edoxaban versus low molecular weight heparin for venous thromboembolism in cancer patients (Dr. Jess Mandel):

  1. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378:615.

Segment on tezacaftor-ivacaftor for cystic fibrosis (Dr. George Mallory):

  1. Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med 2017; 377:2013.
  2. Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017; 377:2024.

Jess Mandel, MD Nothing to disclose

George Mallory, MD Nothing to disclose

Management of suicide risk in children and adolescents; Increasing prevalence of syphilis in the US

Date Released: 2月 7 2018

Today’s episode of UpToDate Talk features Dr. Gregory Simon discussing the management of suicide risk in children and adolescents, and Dr. Khalil Ghanem discussing the increasing prevalence of syphilis in the United States. The second segment begins at 18:10. Dr. Nancy Sokol hosts.

Dr. SimonDr. Gregory Simon is a psychiatrist and senior investigator at the Kaiser Permanente Washington Health Research Institute. He leads the Mental Health Research Network in the US and is an UpToDate author for topics on suicide.
Dr. GhanemDr. Khalil Ghanem is Associate Professor of Medicine at the Johns Hopkins University School of Medicine and a specialist in infectious diseases. Dr. Ghanem is an UpToDate author on a number of topics on sexually transmitted infections.

Segment on management of suicide risk in children and adolescents (Dr. Simon):

  1. Morgan C, Webb RT, Carr MJ, et al. Incidence, clinical management, and mortality risk following self-harm among children and adolescents: cohort study in primary care. BMJ 2017; 359:j4351.

Segment on increasing prevalence of syphilis in the US (Dr. Ghanem):

  1. United States Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2016. (Accessed on October 05, 2017).

Gregory Simon, MD, MPH Grant/Research/Clinical Trial Support: Novartis Pharmaceuticals [Depression in psoriasis].

Khalil Ghanem, MD, PhD Nothing to disclose